Drug intelligence / Profile preview

BBO-8520 + pembrolizumab

Development stage: Unknown
Lead developer: BridgeBio Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

BBO-8520 + pembrolizumab is a combination therapy consisting of BBO-8520, a first-in-class direct and covalent dual inhibitor of KRAS G12C (ON and OFF forms), and pembrolizumab, an anti-PD-1 monoclonal antibody. BBO-8520 binds in the Switch-II/Helix3 pocket of KRAS G12C, covalently modifies the target cysteine, and disables effector binding to both active and inactive forms of KRAS G12C, providing optimal target coverage. This combination aims to simultaneously target cancer cells directly through KRAS inhibition while activating the immune system against the tumor.

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on BBO-8520 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBO-8520 + pembrolizumab.

Explore the full profile